AbbVie raised its long-term guidance for Skyrizi and Rinvoq, two key immunology drugs, on Friday. AbbVie stock inched higher.

The post AbbVie Expects Two Of Its Biggest Drugs To Bring In $27 Billion In 2027. And Neither One Is Humira. appeared first on Investor’s Business Daily.